证券代码：300149 证券简称：睿智医药 公告编号：2026-02 睿智医药科技股份有限公司 关于担保进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 睿智医药科技股份有限公司（以下简称"公司"）分别于 2025 年 4 月 27 日、 2025 年5 月 30日召开第六届董事会第六次会议、第六届监事会第六次会议和 2024 年年度股东会，审议通过了《关于向银行等金融机构申请综合授信额度并提供担 保的议案》，同意 2025 年度公司为子公司（含子公司之间）提供担保额度合计为 不超过人民币 18,000 万元。具体内容详见公司于 2025 年 4 月 29 日在巨潮资讯网 （www.cninfo.com.cn）上披露的《关于向银行等金融机构申请综合授信额度并提 供担保的公告》（公告编号：2025-26）。 公司于 2025 年 9 月 8 日召开第六届董事会第十二次会议，审议通过了《关于 为子公司与关联方开展融资租赁业务提供担保暨关联交易的议案》，为适度利用 融资渠道，优化融资结构，满足经营发展需求，同意公司为全资子公司上海睿智 医 ...

Core Viewpoint - As of January 10, the number of shareholders for Ruizhi Pharmaceutical (300149) reached 39,034 households [1] Company Summary - The company actively engages with investors through interactive platforms, indicating a commitment to transparency and communication [1]

Group 1 - Huaseng Tiancheng's revenue from AI-related business currently accounts for a low proportion of the company's overall operating income [1] - Xinhua Department Store has no plans to inject assets related to semiconductors, integrated circuits, or chips into the company [1] - Triangle Tire plans to invest 3.219 billion yuan to establish a new project in Cambodia with an annual production capacity of 7 million high-performance radial tires [1] Group 2 - Tianhong Co., Ltd.'s subsidiary has won a bid for an AI service procurement project from AVIC Technology [1] - Xinghua New Materials intends to acquire at least 51% of Tian Kuan Technology's shares [1] - Luxshare Precision plans to repurchase company shares worth between 1 billion to 2 billion yuan [1] Group 3 - Rui Zhi Pharmaceutical's Liang Yufeng and Yu Xianwen plan to collectively reduce their holdings by no more than 6% [1] - Tian Sheng New Materials plans to raise no more than 253 million yuan through a private placement to Rongsheng Zhizhi [1] - Zhongchuang Zhiling intends to issue convertible bonds to raise no more than 4.35 billion yuan for investment in high-end components for the new energy vehicle industry [2]

Group 1: Company Strategy - The company's current strategic direction is driven by a "full-package strategy + CVC ecological investment" model, aiming to strengthen its full-chain service capabilities from PCC to IND to NDA while expanding service coverage and technical depth [2] - The company has participated in projects such as the Shenzhen Luohu Donghai Wisdom Pharmaceutical Industry Investment Fund, leveraging its "chain master" role to integrate industry resources and achieve win-win development [3] Group 2: Customer Structure - The customer base is diverse, including multinational pharmaceutical companies (MNCs), biotech firms, and research institutions, with mid-sized biotech companies and MNCs forming the core customer group [4] - These key customers are characterized by stable development, ample funding, and controllable project advancement, providing a solid foundation for the company's ongoing business growth [4] Group 3: AI Technology Integration - The company has over 20 years of R&D experience, utilizing AI technology to enhance research efficiency, shorten development cycles, and reduce the number of candidate compounds, thereby lowering overall R&D costs [4] - A systematic approach is being taken to build a "scientific research intelligent hub platform," improving efficiency in daily operations and applying AI in critical areas such as antibody discovery and drug property prediction [5] Group 4: Nucleic Acid Field Development - The company has established a comprehensive innovative platform covering large and small nucleic acids, with a complete technical system that includes chemical modifications and innovative monomers [6] - Collaborations with companies like Saint Nor Pharmaceutical and Haiyou Biology have been initiated to strengthen capabilities in the nucleic acid sector [7] Group 5: Performance Goals - The three-year stock incentive performance targets have a gradually increasing range due to the initial phase of strategic execution, focusing on overcoming current challenges and key tasks such as the CVC industry fund layout for 2024-2025 [7] - The strategic effects are expected to gradually manifest from 2026 to 2027, leading to an accelerated release cycle of full-package orders, hence the broader performance target range [7]

Summary of Key Points Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership and investor sentiment in the market [1]. Shareholder Reductions - **New Chai Co., Ltd.**: General Manager Zhu Guanlan plans to reduce holdings by up to 1% [1]. - **Ruizhi Pharmaceutical**: Shareholders Liang Yufeng and Yu Xianwen intend to collectively reduce their stakes by no more than 6% [1]. - **Aidi Te**: Shareholders Junlian Xinkang and HAL plan to reduce their stakes by up to 3% [1]. - **Feiwo Technology**: Shareholder Chang Defuwo intends to reduce holdings by up to 1% [1]. - **Feili Hua**: The actual controller plans to reduce holdings by up to 1% [1]. - **Shanwaishan**: Major shareholder Liu Yunjun plans to reduce holdings by no more than 1% [1]. - **Hongchuan Wisdom**: Shareholder Hongchuan Supply Chain intends to reduce holdings by up to 2% [1]. - **Jiuzhitang**: General Manager Li Zhengguo plans to reduce holdings by no more than 2% [1]. - **Yifan Transmission**: Chairman Liu Jincheng intends to reduce holdings by up to 3% [1]. - **Zhongyuan Home**: Chairman and General Manager Cao Yong plan to collectively reduce holdings by 2.51% [1]. - **Huafeng Aluminum**: Shareholder You Xiaohua has completed a reduction of 2.17% [1]. - **Beijing Renli**: Shareholder Tianjin Rongheng reduced holdings by 6.0399 million shares [1]. - **Hu Silicon Industry**: Major shareholder Da Fund has cumulatively reduced holdings by 0.97% [1]. Other Notable Information - **ST Huawang**: The company's stock may face delisting [1]. - **Kunlun Wanwei**: The company expects a negative net profit attributable to shareholders for the year 2025 [1].

Core Viewpoint - The major shareholders of Ruizhi Pharmaceutical (300149.SZ) plan to reduce their holdings in the company through centralized bidding or block trading within three months after the announcement [1] Group 1: Shareholder Reductions - Shareholder Liang Yufeng, holding 26,185,660 shares (5.26% of total shares), intends to reduce up to 14,938,919 shares (3% of total shares) [1] - Shareholder Yu Xianwen, holding 25,000,000 shares (5.02% of total shares), also plans to reduce up to 14,938,919 shares (3% of total shares) [1]

Group 1 - The core point of the article is that two major shareholders of Ruizhi Pharmaceutical plan to reduce their holdings in the company by a total of 14,938,919 shares, which represents 3% of the total share capital [2] - Shareholder Liang Yufeng, who holds 26,185,660 shares (5.26% of total shares), intends to sell up to 14,938,919 shares within three months after a 15 trading day period from the announcement date [2] - Shareholder Yu Xianwen, who holds 25,000,000 shares (5.02% of total shares), also plans to reduce his holdings by the same amount of 14,938,919 shares under similar conditions [2]

Group 1 - The core point of the article is that Ruizhi Pharmaceutical (300149) announced that shareholders Liang Yufeng and Yu Xianwen plan to collectively reduce their holdings by up to 6% of the company's shares [1] Group 2 - Shareholder Liang Yufeng, who holds 26.1857 million shares (5.26% of total shares), intends to reduce his holdings by up to 14.9389 million shares (3% of total shares) within three months after a 15 trading day period from the announcement date [1] - Shareholder Yu Xianwen, who holds 25 million shares (5.02% of total shares), also plans to reduce his holdings by up to 14.9389 million shares (3% of total shares) within the same timeframe [1]

Core Viewpoint - The major shareholders of Ruizhi Pharmaceutical (300149.SZ) plan to reduce their holdings by a total of 14.9389 million shares, representing 3% of the company's total share capital, within three months after a 15-trading-day notice period [1] Group 1: Shareholder Actions - Shareholder Liang Yufeng intends to reduce her stake by up to 14.9389 million shares, which is 3% of the total share capital, through centralized bidding or block trading within three months after the notice period [1] - Shareholder Yu Xianwen also plans to reduce his holdings by the same amount of 14.9389 million shares, accounting for 3% of the total share capital, using similar methods within the specified timeframe [1]

Core Viewpoint - The major shareholders of Ruizhi Pharmaceutical (300149.SZ) plan to reduce their holdings by a total of 14.9389 million shares, representing 3% of the company's total share capital, within three months after a 15-trading-day period from the announcement date [1] Shareholder Reduction Plans - Shareholder Liang Yufeng intends to reduce her stake by up to 14.9389 million shares, which is 3% of the total share capital, through centralized bidding or block trading within three months after the specified period [1] - Shareholder Yu Xianwen also plans to reduce his holdings by the same amount of 14.9389 million shares, accounting for 3% of the total share capital, using similar methods within the same timeframe [1]